Day 1: Tuesday, 12/10/2019

Media | Gallery | Contact

Home / 2019 SABCS^® / Program / Daily Schedule / Day 1: Tuesday, 12/10/2019

Tuesday \| Wednesday \| Thursday \| Friday \| Saturday
TUESDAY, DECEMBER 10, 2019
8:00 am - 7:00 pm		REGISTRATION - Main Lobby
		Pre-registered attendees can obtain materials. Those who have not yet registered may do so.

11:45 am - 1:45 pm		WORKSHOPS
		Molecular Biology in Breast Oncology - Hemisfair Ballroom - 3rd Level Moderator: Carlos L. Arteaga, MD UT Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas, TX Antibody-drug conjugates in cancer: Principles for synthesis and preclinical development Gail Lewis Phillips Genentech, Inc. South San Francisco, CA Defining a cancer dependency map William C. Hahn, MD, PhD Dana-Farber Cancer Institute Boston, MA Approaches to targeting the anti-apoptotic machinery in breast cancer Geoffrey Lindeman, MBBS, FRACP, PhD The Walter & Eliza Hall Institute of Medical Research Parkville, AUSTRALIA Novel target discovery by longitudinal deep spatial & molecular analysis of breast cancers Joe Gray, PhD Oregon Health & Science University Portland, OR

		Developing Novel Therapeutics in the Metastatic Setting - Stars at Night Ballroom 1&2 - 3rd Level Moderator: Virginia G. Kaklamani, MD UT Health San Antonio San Antonio, TX Window versus neoadjuvant trial - choose wisely Alastair M. Thompson, BSc (Hons), MB ChB, FRCSEd Baylor College of Medicine Houston, TX Therapeutic development in the era of precision medicine: Paradigm shift from maximum tolerated dose (MTD) to optimal biological dose (OBD) Aditya Bardia, MD, MPH Massachusetts General Hospital Harvard Medical School Boston, MA Design and analysis of window and neoadjuvant trials Meredith Regan, ScD Dana-Farber Cancer Institute Harvard Medical School Boston, MA How to talk to patients about participating in clinical trials Patricia Spears, BSc UNC Lineberger Comprehensive Cancer Center Chapel Hill, NC

1:45 pm - 2:00 pm		BREAK

2:00 pm - 7:00 pm		EDUCATIONAL SESSIONS - Stars at Night Ballrooms 1&2, 3, 4 and Hemisfair Ballroom - 3rd Level Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

2:00 pm - 3:30 pm		Immunotherapy for Triple-Negative Breast Cancer - Stars at Night Ballroom 3 - 3rd Level Moderator: Sylvia Adams, MD NYU Langone Health New York, NY The emerging role of immunotherapy for the treatment of early and advanced breast cancer Rita Nanda, MD University of Chicago Chicago, IL Detecting and managing immunotherapy-related toxicities wisely Peter Schmid, MD, PhD Barts Cancer Institute London, UNITED KINGDOM Assessment of PD-L1 in breast cancer to predict response to immunotherapy David L. Rimm, MD, PhD Yale University School of Medicine New Haven, CT SABCS and the American Society for Radiation Oncology (ASTRO) present Evolving Opportunities to Personalize Radiation Decisions - Stars at Night Ballroom 4 - 3rd Level Moderator: Reshma Jagsi, MD, DPhil University of Michigan Ann Arbor, MI Guiding decisions to omit radiotherapy after breast-conserving surgery for DCIS. Can genomic biomarkers help? Eileen Rakovitch, MD, MSc, FRCPC Sunnybrook Health Sciences Centre Toronto, CANADA Evolving opportunities to personalize radiation decisions - Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer Corey Speers, MD, PhD University of Michigan Ann Arbor, MI Guiding selection of RT approach after lumpectomy Simona Shaitelman, MD University of Texas MD Anderson Cancer Center Houston, TX Breast Cancer Prevention – Stars at Night Ballroom 1&2 - 3rd Level Moderator: Judy E. Garber, MD, MPH Dana-Farber Cancer Institute Boston, MA Targeted approach to breast cancer surveillance in high risk women: Update of the newest technologies and how to use them Maxine S. Jochelson, MD Memorial Sloan Kettering Cancer Center New York, NY Sooner or later: considering risk over time, and implications for management Seema A. Khan, MD Northwestern University Chicago, IL Low dose tamoxifen and other approaches to improve chemoprevention uptake Andrea De Censi, MD E.O. Ospedali Galliera Genova, ITALY Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations ‐ Hemisfair Ballroom - 3rd Level Moderator: Carlos L. Arteaga, MD UT Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas, TX Adaptive resistance to hormonal therapy Suzanne A.W. Fuqua, PhD Baylor College of Medicine Houston, TX Single cell transcriptomics reveals multi-step adaptations to endocrine therapy Luca Magnani, PhD Imperial College London London, UNITED KINGDOM The genomic landscape of endocrine-resistant metastatic breast cancer Pedram Razavi, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY

3:45 pm - 5:15 pm		SABCS with the Society of Surgical Oncology present Multidisciplinary Approaches to Optimizing Surgical Therapy for Hormone Receptor Positive Breast Cancer – Stars at Night Ballroom 3 - 3rd Level Moderator: Armando Giuliano, MD Cedars-Sinai Medical Center Los Angeles, CA Neoadjuvant therapy for hormone receptor positive breast cancer: Challenges and advances Otto Metzger, MD Dana-Farber Cancer Institute Boston, MA Regional management of the axilla prior to systemic therapy Melissa L. Pilewskie, MD Memorial Sloan Kettering Cancer Center New York, NY Surgical considerations AFTER preoperative therapy for hormone receptor positive breast cancer Tari Ann King, MD Dana-Farber Cancer Institute Brigham and Women's Cancer Center Boston, MA Implementation of Genetic Testing in Breast Cancer Patients – Stars at Night Ballroom 4 - 3rd Level Moderator: Virginia G. Kaklamani, MD UT Health San Antonio San Antonio, TX Who should have germline testing for hereditary breast cancer? Nadine Tung, MD Beth Israel Deaconess Medical Center Boston, MA Alternative practical models for genetic services in the era of increased demand Banu Arun, MD University of Texas MD Anderson Cancer Center Houston, TX Breast cancer genetic testing: moving from cancer risk assessment to therapeutic biomarker Judith Balmaña, MD, PhD Vall d'Hebron University Hospital Barcelona, SPAIN Conversations on Tough Topics Surrounding Cancer Care – Stars at Night Ballroom 1&2 - 3rd Level Moderator: Susan Rafte Community Advocate, Baylor College of Medicine Breast Center Houston, TX Progression of disease and end of life: How to break bad news Eric P. Winer, MD Dana-Farber Cancer Institute Boston, MA The toll on healthcare providers Sharon H. Giordano, MD, MPH, FASCO University of Texas MD Anderson Cancer Center Houston, TX The financial costs and burden of breast cancer care Rachel A. Greenup, MD, MPH Duke Cancer Institute Durham, NC Panel Discussion Thelma P. Brown University of Alabama at Birmingham Birmingham, AL Katherine O'Brien Metastatic Breast Cancer Network New York, NY Endocrine Therapy in 2020 - Hemisfair Ballroom - 3rd Level Moderator: Mothaffar Rimawi, MD Baylor College of Medicine Houston, TX Adjuvant endocrine therapy in 2020: It's complicated Ruth O'Regan, MD University of Wisconsin Madison Madison, WI Future directions in endocrine therapy for advanced HER+/HER2- breast cancer Erica L. Mayer, MD, MPH Dana-Farber Cancer Institute Harvard Medical School Boston, MA Everything comes at a price - Toxicity, cost and adherence to endocrine therapy Dawn Hershman, MD Columbia University Medical Center New York Presbyterian Hospital New York, NY

5:30 pm - 7:00 pm		Discussing Risk in the Context of GEP Testing - Stars at Night Ballroom 3 - 3rd Level Moderator: Lesley Fallowfield, BSc, DPhil Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School Brighton, UNITED KINGDOM Discussing risk & uncertainty with patients in the context of GEP testing Lesley Fallowfield, BSc, DPhil Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School Brighton, UNITED KINGDOM Communicating risk information, talking by numbers Valerie Ann Jenkins, DPhil, BSc Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School Brighton, UNITED KINGDOM Breast Cell Fate Control and Plasticity – Stars at Night Ballroom 4 - 3rd Level Moderator: Yi Li, PhD Baylor College of Medicine Houston, TX Cellular plasticity, fate, potential and lineage commitment of mammary gland stem cells Cedric Blanpain, MD, PhD Universite Libre de Bruxelles Bruxelles, BELGIUM Understanding breast cancer using a developmental perspective Geoffrey Wahl, PhD Salk Institute for Biological Studies La Jolla, CA Cell fate plasticity during breast cancer development - where is the translational utility? Christina Scheel, MD Helmholtz Center Munich Institute of Stem Cell Research Neuherberg, GERMANY Tailoring Adjuvant Therapies Based on Neoadjuvant Response - Stars at Night Ballroom 1&2 - 3rd Level Moderator: Charles E. Geyer, MD Virginia Commonwealth University Massey Cancer Center Richmond, VA The biology and plasticity of residual disease after neoadjuvant treatment Charles M. Perou, PhD University of North Carolina Chapel Hill, NC Neoadjuvant systemic treatment (NST): Tailoring response by subtype Jenny C. Chang, MD Houston Methodist Hospital Houston, TX Local treatments in patients who achieve pathologic complete response Julia White, MD The Ohio State University Columbus, OH Targeted Treatment Beyond PARP1 Inhibition - Hemisfair Ballroom - 3rd Level Moderator: Alexander Bishop, DPhil Greehey Children's Cancer Research Institute UT Health San Antonio San Antonio, TX Clinical indications of PARP1 inhibitors and other targets Melinda L. Telli, MD Stanford University Medical Center Stanford, CA Targeted DNA repair in cancer and new NUDT5 inhibitors to block hormone signalling to target breast cancer Thomas Helleday, PhD University of Sheffield Sheffield, UNITED KINGDOM Clinically relevant biomarkers of PARP1 inhibitor resistance and indicators of targeted combinatorial treatments Violeta Serra, PhD Vall d'Hebron Institute of Oncology Barcelona, SPAIN

7:30 pm - 10:00 pm		OPEN SATELLITE EVENT presented by PVI, Peer View Institute for Medical Education - Marriott Rivercenter On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum For further information and to register for this event, visit : PeerView.com/TNBC19